Abstract

To evaluate the therapeutic effects of Baoxin’an capsules combined with trimetazidine tablets on type 2 diabetes with chronic heart failure. A total of 168 patients with type 2 diabetes complicated with chronic heart failure treated in our hospital from January 2016 to December 2017 were selected. They were randomly divided into two groups (n=84), both receiving diet control. On the basis of routine medication, the control group was given trimetazidine tablets. The observation group was administered with Baoxin’an capsules plus trimetazidine tablets. 30 d were employed as a course of treatment and the entire duration was 6 mo. The clinical symptoms, cardiac function classifications and the changes of plasma N-terminal pro–Btype natriuretic peptide and high-sensitivity C-reactive protein levels before and after treatment were compared. The overall effective rate of the observation group was 90.48 % which was significantly higher than that of the control group (73.81 %) (χ2=7.954, p=0.005). The increases in blood flow peak velocity ratio of left ventricular diastolic late phase to early phase, left ventricular ejection fraction, cardiac output and stroke volume of the observation group were significantly higher than those of the control group (p<0.05). After treatment, fasting plasma glucose, plasma pro–B-type natriuretic peptide and serum high-sensitivity C-reactive protein levels were significantly decreased (p<0.01). The above indices of the observation group were all significantly lower than those of the control group (p<0.05). After treatment, there were no obvious abnormal changes in routine blood, routine urine or liver and kidney function tests. Baoxin’an capsules in combination with trimetazidine tablets can inhibit non-specific inflammatory reaction of type 2 diabetes with chronic heart failure, alleviate myocardial damage and ventricular remodeling, improve cardiac function and enhance clinical therapeutic effects.